219 related articles for article (PubMed ID: 18846335)
1. Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma.
Yao Y; Zou R; Liu X; Jiang J; Huang Q; He Y; Li M; Wang S; Zhou J; Ma D; Xu G
J Huazhong Univ Sci Technolog Med Sci; 2008 Oct; 28(5):543-8. PubMed ID: 18846335
[TBL] [Abstract][Full Text] [Related]
2. PPARgamma agonists inhibit TGF-beta-PKA signaling in glomerulosclerosis.
Zou R; Xu G; Liu XC; Han M; Jiang JJ; Huang Q; He Y; Yao Y
Acta Pharmacol Sin; 2010 Jan; 31(1):43-50. PubMed ID: 20037602
[TBL] [Abstract][Full Text] [Related]
3. Valsartan and telmisartan abrogate angiotensin II-induced downregulation of ABCA1 expression via AT1 receptor, rather than AT2 receptor or PPARγ activation.
Chen HY; Xu Z; Chen LF; Wang W; Fang Q; Yan XW
J Cardiovasc Pharmacol; 2012 Jun; 59(6):570-5. PubMed ID: 22392065
[TBL] [Abstract][Full Text] [Related]
4. Telmisartan activates endogenous peroxisome proliferator-activated receptor-δ and may have anti-fibrotic effects in human mesangial cells.
Mikami D; Kimura H; Kamiyama K; Torii K; Kasuno K; Takahashi N; Yoshida H; Iwano M
Hypertens Res; 2014 May; 37(5):422-31. PubMed ID: 24352213
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan exerts renoprotective actions via peroxisome proliferator-activated receptor-γ/hepatocyte growth factor pathway independent of angiotensin II type 1 receptor blockade.
Kusunoki H; Taniyama Y; Azuma J; Iekushi K; Sanada F; Otsu R; Iwabayashi M; Okayama K; Rakugi H; Morishita R
Hypertension; 2012 Feb; 59(2):308-16. PubMed ID: 22252391
[TBL] [Abstract][Full Text] [Related]
6. Different effects of telmisartan and valsartan on human aortic vascular smooth muscle cell proliferation.
Wang L; Zhao L; Zhang D; Chen JZ; Xue JL
Chin Med J (Engl); 2012 Jun; 125(12):2200-4. PubMed ID: 22884153
[TBL] [Abstract][Full Text] [Related]
7. Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.
Yamamoto K; Ohishi M; Ho C; Kurtz TW; Rakugi H
Hypertension; 2009 Dec; 54(6):1353-9. PubMed ID: 19822796
[TBL] [Abstract][Full Text] [Related]
8. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma.
Imayama I; Ichiki T; Inanaga K; Ohtsubo H; Fukuyama K; Ono H; Hashiguchi Y; Sunagawa K
Cardiovasc Res; 2006 Oct; 72(1):184-90. PubMed ID: 16938288
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of vascular angiotensin-converting enzyme by telmisartan via the peroxisome proliferator-activated receptor gamma agonistic property in rats.
Takai S; Jin D; Kimura M; Kirimura K; Sakonjo H; Tanaka K; Miyazaki M
Hypertens Res; 2007 Dec; 30(12):1231-7. PubMed ID: 18344629
[TBL] [Abstract][Full Text] [Related]
10. Telmisartan counteracts TGF-β1 induced epithelial-to-mesenchymal transition via PPAR-γ in human proximal tubule epithelial cells.
Chen Y; Luo Q; Xiong Z; Liang W; Chen L; Xiong Z
Int J Clin Exp Pathol; 2012; 5(6):522-9. PubMed ID: 22949934
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation.
Matsui T; Yamagishi S; Ueda S; Nakamura K; Imaizumi T; Takeuchi M; Inoue H
J Int Med Res; 2007; 35(4):482-9. PubMed ID: 17697525
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma.
Walcher D; Hess K; Heinz P; Petscher K; Vasic D; Kintscher U; Clemenz M; Hartge M; Raps K; Hombach V; Marx N
Hypertension; 2008 Feb; 51(2):259-66. PubMed ID: 18158351
[TBL] [Abstract][Full Text] [Related]
13. Effects of telmisartan and valsartan on insulin sensitivity in obese diabetic mice.
Ushijima K; Takuma M; Ando H; Ishikawa-Kobayashi E; Nozawa M; Maekawa T; Shiga T; Fujimura A
Eur J Pharmacol; 2013 Jan; 698(1-3):505-10. PubMed ID: 23195328
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tumor necrosis factor-alpha-induced interleukin-6 expression by telmisartan through cross-talk of peroxisome proliferator-activated receptor-gamma with nuclear factor kappaB and CCAAT/enhancer-binding protein-beta.
Tian Q; Miyazaki R; Ichiki T; Imayama I; Inanaga K; Ohtsubo H; Yano K; Takeda K; Sunagawa K
Hypertension; 2009 May; 53(5):798-804. PubMed ID: 19289654
[TBL] [Abstract][Full Text] [Related]
15. Telmisartan inhibits vasoconstriction via PPARγ-dependent expression and activation of endothelial nitric oxide synthase.
Yuen CY; Wong WT; Tian XY; Wong SL; Lau CW; Yu J; Tomlinson B; Yao X; Huang Y
Cardiovasc Res; 2011 Apr; 90(1):122-9. PubMed ID: 21156825
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan, an angiotensin II type 1 receptor antagonist, attenuates T-type Ca2+ channel expression in neonatal rat cardiomyocytes.
Morishima M; Wang Y; Akiyoshi Y; Miyamoto S; Ono K
Eur J Pharmacol; 2009 May; 609(1-3):105-12. PubMed ID: 19292980
[TBL] [Abstract][Full Text] [Related]
17. Telmisartan prevents angiotensin II-induced endothelial dysfunction in rabbit aorta via activating HGF/Met system and PPARγ pathway.
Hu ZP; Fang XL; Qian HY; Fang N; Wang BN; Wang Y
Fundam Clin Pharmacol; 2014 Oct; 28(5):501-11. PubMed ID: 24188213
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin inhibition stimulates PPARgamma and the release of visfatin.
Storka A; Vojtassakova E; Mueller M; Kapiotis S; Haider DG; Jungbauer A; Wolzt M
Eur J Clin Invest; 2008 Nov; 38(11):820-6. PubMed ID: 19021699
[TBL] [Abstract][Full Text] [Related]
19. Telmisartan ameliorates hyperglycemia and metabolic profile in nonobese Cohen-Rosenthal diabetic hypertensive rats via peroxisome proliferator activator receptor-gamma activation.
Younis F; Stern N; Limor R; Oron Y; Zangen S; Rosenthal T
Metabolism; 2010 Aug; 59(8):1200-9. PubMed ID: 20070992
[TBL] [Abstract][Full Text] [Related]
20. Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.
Scalera F; Martens-Lobenhoffer J; Bukowska A; Lendeckel U; Täger M; Bode-Böger SM
Hypertension; 2008 Mar; 51(3):696-703. PubMed ID: 18250362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
